advertisement
Abstract #8491 Published in IGR 5-1
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM; The Bimatoprost/Latanoprost Study GroupAmerican Journal of Ophthalmology 2003; 135: 55-63
PURPOSE: To compare the intraocular pressure (IOP)-lowering efficacy and safety of topical bimatoprost 0.03% with latanoprost 0.005%. DESIGN: Multicenter, randomized, investigator-masked clinical trial. METHODS: After washout of glaucoma medications, ocular hypertension or glaucoma patients were randomly assigned to once-daily bimatoprost 0.03% (n = 133) or latanoprost 0.005% (n = 136) for six months. The primary outcome measure was mean change from baseline IOP (8 a.m., 12 p.m., 4 p.m.). Secondary measures included mean IOP, ophthalmological examination, adverse events, and the percentage of patients reaching specific target IOPs. RESULTS: Mean change from baseline IOP was significantly greater for bimatoprost patients than for latanoprost patients at all measurements on each study visit; 1.5 mmHg greater at 8 a.m. (p < 0.001), 2.2 mmHg greater at 12 p.m. (p < 0.001), and 1.2 mmHg greater at 4 p.m. (p = 0.004) at six months. At the end of the study, the percentage of patients achieving a ≥ 20% IOP decrease was 69-82% with bimatoprost and 50-62% with latanoprost (p ≤ 0.003). In addition, the distribution of patients achieving target pressures in each range (≤ 13 to ≤ 15 mmHg, > 15 to ≥ 18 mmHg, and > 18 mmHg) showed that bimatoprost produced lower target pressures compared with latanoprost at all times measured (p ≤ 0.026). Few patients were discontinued for adverse events (six on bimatoprost; five on latanoprost). On ophthalmological examination, conjunctival hyperemia (p < 0.001) and eyelash growth (p = 0.064) were more common in bimatoprost patients. CONCLUSIONS: Bimatoprost is more effective than latanoprost in lowering IOP. Both drugs were well tolerated, with few discontinuations for adverse events.
Dr. R.S. Noecker, University of Arizona, Tucson, AZ, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)